Literature DB >> 8947493

Kinetic and biochemical correlation between sustained p44ERK1 (44 kDa extracellular signal-regulated kinase 1) activation and lysophosphatidic acid-stimulated DNA synthesis in Rat-1 cells.

S J Cook1, F McCormick.   

Abstract

Rat-1 fibroblasts were used to study the role of the sustained activation of extracellular signal-regulated kinase 1 (ERK1) in lysophosphatidic acid (LPA)-stimulated mitogenic signalling. Mitogenic doses of LPA, like serum, stimulated biphasic, sustained, ERK activation that persisted towards the G1/S boundary. The EC50 for LPA-stimulated ERK activation after 10 min, the time of peak response, was 2 orders of magnitude to the left of that for the sustained response after 3 h or that for DNA synthesis after 22 h, with the result that non-mitogenic doses stimulated a maximal peak response but no second phase. To complement these studies, we examined the role of different signal pathways in regulating the sustained and acute phases of ERK activation using defined biochemical inhibitors and mimetics. Activation of protein kinase C and Ca2+ fluxes played a minor and transient role in regulation of ERK1 activity by LPA in Rat-1 cells. Sustained ERK1 activation stimulated by LPA was completely inhibited by pertussis toxin, whereas the early peak response was only partly affected; this is correlated with the specific inhibition of LPA-stimulated DNA synthesis by pertussis toxin. The selective tyrosine kinase inhibitor herbimycin A completely inhibited sustained ERK1 activation by LPA but, again, the early phase of the response was only partially inhibited. In addition, low doses of staurosporine inhibited ERK1 activation by LPA. The effects of herbimycin A and staurosporine were selective for the response to LPA but did not affect that to epidermal growth factor. The results suggest a strong correlation between sustained ERK1 activation and DNA synthesis in LPA-stimulated Rat-1 cells. Furthermore, the two discrete phases of ERK activation by LPA are regulated by a combination of at least two different signalling pathways; the sustained activation of ERK1 in Rat-1 cells proceeds via a G1- or Gzero-mediated pathway which may also involve a tyrosine kinase.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8947493      PMCID: PMC1217923          DOI: 10.1042/bj3200237

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  54 in total

1.  Lysophosphatidate-induced cell proliferation: identification and dissection of signaling pathways mediated by G proteins.

Authors:  E J van Corven; A Groenink; K Jalink; T Eichholtz; W H Moolenaar
Journal:  Cell       Date:  1989-10-06       Impact factor: 41.582

Review 2.  Transmembrane receptors and intracellular pathways that control cell proliferation.

Authors:  J Pouysségur; K Seuwen
Journal:  Annu Rev Physiol       Date:  1992       Impact factor: 19.318

3.  Differential activation of p44mapk (ERK1) by alpha-thrombin and thrombin-receptor peptide agonist.

Authors:  V Vouret-Craviari; E Van Obberghen-Schilling; J C Scimeca; E Van Obberghen; J Pouysségur
Journal:  Biochem J       Date:  1993-01-01       Impact factor: 3.857

4.  Metabolic conversion of the biologically active phospholipid, lysophosphatidic acid, in fibroblasts.

Authors:  R L van der Bend; J de Widt; E J van Corven; W H Moolenaar; W J van Blitterswijk
Journal:  Biochim Biophys Acta       Date:  1992-04-08

5.  Disappearance of Ca2+-sensitive, phospholipid-dependent protein kinase activity in phorbol ester-treated 3T3 cells.

Authors:  A Rodriguez-Pena; E Rozengurt
Journal:  Biochem Biophys Res Commun       Date:  1984-05-16       Impact factor: 3.575

6.  Stimulation of phosphatidylcholine breakdown by thrombin and carbachol but not by tyrosine kinase receptor ligands in cells transfected with M1 muscarinic receptors. Rapid desensitization of phosphocholine-specific (PC) phospholipase D but sustained activity of PC-phospholipase C.

Authors:  F R McKenzie; K Seuwen; J Pouysségur
Journal:  J Biol Chem       Date:  1992-11-15       Impact factor: 5.157

7.  Endothelin rapidly stimulates mitogen-activated protein kinase activity in rat mesangial cells.

Authors:  Y Wang; M S Simonson; J Pouysségur; M J Dunn
Journal:  Biochem J       Date:  1992-10-15       Impact factor: 3.857

8.  Synthetic alpha-thrombin receptor peptides activate G protein-coupled signaling pathways but are unable to induce mitogenesis.

Authors:  V Vouret-Craviari; E Van Obberghen-Schilling; U B Rasmussen; A Pavirani; J P Lecocq; J Pouysségur
Journal:  Mol Biol Cell       Date:  1992-01       Impact factor: 4.138

9.  Ras is essential for nerve growth factor- and phorbol ester-induced tyrosine phosphorylation of MAP kinases.

Authors:  S M Thomas; M DeMarco; G D'Arcangelo; S Halegoua; J S Brugge
Journal:  Cell       Date:  1992-03-20       Impact factor: 41.582

10.  Requirement for c-ras proteins during viral oncogene transformation.

Authors:  M R Smith; S J DeGudicibus; D W Stacey
Journal:  Nature       Date:  1986 Apr 10-16       Impact factor: 49.962

View more
  12 in total

1.  Thrombin inhibits Bim (Bcl-2-interacting mediator of cell death) expression and prevents serum-withdrawal-induced apoptosis via protease-activated receptor 1.

Authors:  Claire J Chalmers; Kathryn Balmanno; Kathryn Hadfield; Rebecca Ley; Simon J Cook
Journal:  Biochem J       Date:  2003-10-01       Impact factor: 3.857

2.  An extracellular signal-regulated kinase 1- and 2-dependent program of chromatin trafficking of c-Fos and Fra-1 is required for cyclin D1 expression during cell cycle reentry.

Authors:  Peter M Burch; Ziqiang Yuan; Anne Loonen; Nicholas H Heintz
Journal:  Mol Cell Biol       Date:  2004-06       Impact factor: 4.272

3.  A positive feedback loop couples Ras activation and CD44 alternative splicing.

Authors:  Chonghui Cheng; Michael B Yaffe; Phillip A Sharp
Journal:  Genes Dev       Date:  2006-07-01       Impact factor: 11.361

4.  Differential regulation of extracellular signal-regulated protein kinase 1 and Jun N-terminal kinase 1 by Ca2+ and protein kinase C in endothelin-stimulated Rat-1 cells.

Authors:  K Cadwallader; J Beltman; F McCormick; S Cook
Journal:  Biochem J       Date:  1997-02-01       Impact factor: 3.857

Review 5.  Extracellular-Regulated Kinases: Signaling From Ras to ERK Substrates to Control Biological Outcomes.

Authors:  Scott T Eblen
Journal:  Adv Cancer Res       Date:  2018-03-02       Impact factor: 6.242

6.  The repertoire of fos and jun proteins expressed during the G1 phase of the cell cycle is determined by the duration of mitogen-activated protein kinase activation.

Authors:  S J Cook; N Aziz; M McMahon
Journal:  Mol Cell Biol       Date:  1999-01       Impact factor: 4.272

7.  Ligand-specific sequential regulation of transcription factors for differentiation of MCF-7 cells.

Authors:  Yuko Saeki; Takaho Endo; Kaori Ide; Takeshi Nagashima; Noriko Yumoto; Tetsuro Toyoda; Harukazu Suzuki; Yoshihide Hayashizaki; Yoshiyuki Sakaki; Mariko Okada-Hatakeyama
Journal:  BMC Genomics       Date:  2009-11-20       Impact factor: 3.969

8.  The effects of low-dose nepsilon-(carboxymethyl)lysine (CML) and nepsilon-(carboxyethyl)lysine (CEL), two main glycation free adducts considered as potential uremic toxins, on endothelial progenitor cell function.

Authors:  Jinzhou Zhu; Ke Yang; Yajun Jing; Run Du; Zhenbin Zhu; Lin Lu; Ruiyan Zhang
Journal:  Cardiovasc Diabetol       Date:  2012-08-01       Impact factor: 9.951

9.  FGF15 promotes neurogenesis and opposes FGF8 function during neocortical development.

Authors:  Ugo Borello; Inma Cobos; Jason E Long; John R McWhirter; Cornelis Murre; John L R Rubenstein
Journal:  Neural Dev       Date:  2008-07-14       Impact factor: 3.842

10.  Lysophosphatidic acid enhances survival of human CD34(+) cells in ischemic conditions.

Authors:  Ivana Kostic; Isabel Fidalgo-Carvalho; Sezin Aday; Helena Vazão; Tiago Carvalheiro; Mário Grãos; António Duarte; Carla Cardoso; Lino Gonçalves; Lina Carvalho; Artur Paiva; Lino Ferreira
Journal:  Sci Rep       Date:  2015-11-10       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.